Surge in Options Trading Volume for GameStop and MicroStrategy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 06 2026
0mins
Should l Buy SLNO?
Source: NASDAQ.COM
- GameStop Options Volume: GameStop Corp saw options trading volume of 80,627 contracts, equivalent to approximately 8.1 million shares, representing about 139% of its average daily trading volume of 5.8 million shares over the past month, indicating strong market interest.
- High Strike Demand: Notably, the $23.50 strike call option expiring on April 10, 2026, has seen 6,715 contracts traded today, representing around 671,500 underlying shares, suggesting investor expectations for future price increases.
- MicroStrategy Options Volume: Concurrently, MicroStrategy Inc recorded options trading volume of 236,549 contracts, translating to approximately 23.7 million shares, or about 121.4% of its average daily trading volume of 19.5 million shares, highlighting active trading in this stock.
- Strike Price Focus: For the $130 strike call option expiring on April 10, 2026, 8,705 contracts have been traded today, representing approximately 870,500 underlying shares, reflecting optimistic sentiment regarding MicroStrategy's future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLNO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLNO
Wall Street analysts forecast SLNO stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 52.570
Low
75.00
Averages
110.50
High
125.00
Current: 52.570
Low
75.00
Averages
110.50
High
125.00
About SLNO
Soleno Therapeutics, Inc. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its first commercial product, VYKAT XR (diazoxide choline) extended-release tablets, is a once-daily oral treatment for hyperphagia in adults and children four years of age and older with Prader-Willi syndrome (PWS). VYKAT XR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. The KATP channels play a central role in the regulation of a number of physiological processes which may otherwise be dysregulated, contributing to the pathophysiology of several diseases. In the context of the underlying genetic or structural defects in PWS, these pathophysiological processes may cumulatively contribute to increases in appetite and aggressive food seeking, lack of satiety, accumulation of excess body fat and the establishment and perpetuation of the obese state. PWS is a rare, complex genetic neurobehavioral/metabolic disorder.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Soleno Therapeutics Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Soleno Therapeutics (NASDAQ: SLNO) common stock between March 26, 2025, and November 4, 2025, that they must apply to be lead plaintiff by May 5, 2026, or risk losing the opportunity to represent other investors in the class action.
- Lawsuit Background: The lawsuit alleges that Soleno misrepresented safety concerns related to its DCCR drug during clinical trials, including significant issues like fluid retention in participants, leading to investor losses when the true risks were revealed, highlighting the company's inadequate risk management prior to commercialization.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, while also achieving the largest securities class action settlement against a Chinese company in 2017, demonstrating its strong capabilities and successful track record in this field.
- Investor Guidance: Investors are advised to be cautious when selecting legal counsel, with Rosen Law Firm recommending choosing attorneys with proven success in securities class actions to ensure optimal representation during litigation and avoid firms that merely act as intermediaries.
See More
Class Action Notice for Soleno Therapeutics Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Soleno Therapeutics (NASDAQ:SLNO) common stock between March 26, 2025, and November 4, 2025, that they must apply to be lead plaintiff by May 5, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Soleno concealed significant safety concerns related to its DCCR drug during clinical trials, resulting in investors facing greater safety risks and potential legal repercussions post-commercialization.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its successful track record and extensive experience in this field.
- Investor Selection Advice: Investors are advised to carefully choose law firms with proven success to ensure effective legal support in class actions, avoiding firms that merely act as intermediaries without litigation experience.
See More
Soleno Therapeutics Securities Class Action Reminder
- Lawsuit Background: Hagens Berman reminds investors of the pending securities class action against Soleno Therapeutics (NASDAQ:SLNO), with a lead plaintiff deadline of May 5, 2026, for those who purchased shares between March 26 and November 4, 2025.
- Safety Risk Allegations: The lawsuit alleges that Soleno misrepresented the safety and commercial viability of its flagship product, VYKAT™ XR (DCCR), for treating Prader-Willi syndrome, leading to significant investor losses.
- Stock Price Plunge: On November 4, 2025, Soleno reported Q3 results, admitting disruptions in DCCR's launch, which caused a 27% drop in stock price in a single day, reflecting market disappointment in its commercial prospects.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to utilize the SEC Whistleblower program, where providing original information may yield rewards of up to 30% of any successful recovery, further aiding the investigation into Soleno.
See More
Class Action Lawsuits Filed Against Boston Scientific and Others
- Boston Scientific Lawsuit: Boston Scientific faces a class action lawsuit for failing to disclose that its U.S. electrophysiology segment's growth rate was unsustainable, with investors able to file as lead plaintiffs by May 4, 2026, potentially leading to stock price pressure and diminished market confidence.
- Eos Energy Issues: Eos Energy is accused in a class action of failing to ramp up production capacity and experiencing excessive battery line downtime, with a lead plaintiff deadline of May 5, 2026, which could impact future financing and market performance.
- Soleno Therapeutics Risks: Soleno Therapeutics is being sued for concealing safety concerns in its DCCR clinical trial, with investors able to apply as lead plaintiffs by May 5, 2026, and a successful lawsuit could result in significant compensation liabilities and reputational damage for the company.
- Nektar Therapeutics Trial Issues: Nektar Therapeutics is facing a lawsuit for not adhering to standards in its REZOLVE-AA trial, with a lead plaintiff deadline of May 5, 2026, and if the lawsuit is successful, it could severely impact the company's future R&D and market outlook.
See More
Class Action Lawsuit Filed Against Soleno Therapeutics, Inc.
- Lawsuit Background: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Soleno Therapeutics and its executives, seeking damages for investors who purchased Soleno securities between March 26 and November 4, 2025, highlighting significant investor concerns regarding corporate transparency.
- Insufficient Safety Disclosure: The complaint alleges that Soleno failed to adequately disclose safety concerns related to its DCCR clinical trials, including issues of fluid retention in participants, which could lead investors to misjudge the drug's commercial prospects.
- Commercial Viability Risks: The undisclosed safety risks raise serious questions about DCCR's commercial viability, potentially resulting in increased patient discontinuation rates, decreased prescriber willingness, and significant legal and reputational risks, thereby impacting the company's market performance.
- Investor Action Call: Affected investors are encouraged to apply to be lead plaintiffs by May 5, 2026, to share in any potential recovery from the lawsuit, underscoring the importance of legal avenues in protecting investor rights.
See More
Soleno Therapeutics Faces Securities Class Action Lawsuit
- Lawsuit Background: Hagens Berman reminds investors that Soleno Therapeutics (NASDAQ: SLNO) is facing a class action lawsuit for failing to disclose safety risks, urging investors to submit claims by May 5, 2026, for stock purchases made between March 26 and November 4, 2025.
- Safety Risk Allegations: The lawsuit alleges that Soleno concealed significant safety concerns regarding its flagship product VYKAT™ XR, including risks of fluid retention and heart failure in children, which could severely impact the company's reputation and future sales.
- Data Integrity Issues: Reports indicate that Soleno's Phase 3 clinical trials relied on a controversial physician whose data showed inconsistencies, potentially eroding investor trust in the company's data and affecting stock performance.
- Stock Price Volatility: On November 4, 2025, Soleno admitted to disruptions in the launch of DCCR, leading to a 27% drop in stock price in a single day, reflecting a severe lack of market confidence in the company's future prospects and potentially hindering future financing capabilities.
See More
Soleno Therapeutics Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Soleno Therapeutics (NASDAQ: SLNO) common stock between March 26, 2025, and November 4, 2025, that they must apply to be lead plaintiff by May 5, 2026, or risk losing the opportunity to represent other investors in the class action.
- Lawsuit Background: The lawsuit alleges that Soleno misrepresented safety concerns related to its DCCR drug during clinical trials, including significant issues like fluid retention in participants, leading to investor losses when the true risks were revealed, highlighting the company's inadequate risk management prior to commercialization.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, while also achieving the largest securities class action settlement against a Chinese company in 2017, demonstrating its strong capabilities and successful track record in this field.
- Investor Guidance: Investors are advised to be cautious when selecting legal counsel, with Rosen Law Firm recommending choosing attorneys with proven success in securities class actions to ensure optimal representation during litigation and avoid firms that merely act as intermediaries.
See More
Class Action Notice for Soleno Therapeutics Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Soleno Therapeutics (NASDAQ:SLNO) common stock between March 26, 2025, and November 4, 2025, that they must apply to be lead plaintiff by May 5, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Soleno concealed significant safety concerns related to its DCCR drug during clinical trials, resulting in investors facing greater safety risks and potential legal repercussions post-commercialization.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its successful track record and extensive experience in this field.
- Investor Selection Advice: Investors are advised to carefully choose law firms with proven success to ensure effective legal support in class actions, avoiding firms that merely act as intermediaries without litigation experience.
See More
Soleno Therapeutics Securities Class Action Reminder
- Lawsuit Background: Hagens Berman reminds investors of the pending securities class action against Soleno Therapeutics (NASDAQ:SLNO), with a lead plaintiff deadline of May 5, 2026, for those who purchased shares between March 26 and November 4, 2025.
- Safety Risk Allegations: The lawsuit alleges that Soleno misrepresented the safety and commercial viability of its flagship product, VYKAT™ XR (DCCR), for treating Prader-Willi syndrome, leading to significant investor losses.
- Stock Price Plunge: On November 4, 2025, Soleno reported Q3 results, admitting disruptions in DCCR's launch, which caused a 27% drop in stock price in a single day, reflecting market disappointment in its commercial prospects.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to utilize the SEC Whistleblower program, where providing original information may yield rewards of up to 30% of any successful recovery, further aiding the investigation into Soleno.
See More
Class Action Lawsuits Filed Against Boston Scientific and Others
- Boston Scientific Lawsuit: Boston Scientific faces a class action lawsuit for failing to disclose that its U.S. electrophysiology segment's growth rate was unsustainable, with investors able to file as lead plaintiffs by May 4, 2026, potentially leading to stock price pressure and diminished market confidence.
- Eos Energy Issues: Eos Energy is accused in a class action of failing to ramp up production capacity and experiencing excessive battery line downtime, with a lead plaintiff deadline of May 5, 2026, which could impact future financing and market performance.
- Soleno Therapeutics Risks: Soleno Therapeutics is being sued for concealing safety concerns in its DCCR clinical trial, with investors able to apply as lead plaintiffs by May 5, 2026, and a successful lawsuit could result in significant compensation liabilities and reputational damage for the company.
- Nektar Therapeutics Trial Issues: Nektar Therapeutics is facing a lawsuit for not adhering to standards in its REZOLVE-AA trial, with a lead plaintiff deadline of May 5, 2026, and if the lawsuit is successful, it could severely impact the company's future R&D and market outlook.
See More
Class Action Lawsuit Filed Against Soleno Therapeutics, Inc.
- Lawsuit Background: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Soleno Therapeutics and its executives, seeking damages for investors who purchased Soleno securities between March 26 and November 4, 2025, highlighting significant investor concerns regarding corporate transparency.
- Insufficient Safety Disclosure: The complaint alleges that Soleno failed to adequately disclose safety concerns related to its DCCR clinical trials, including issues of fluid retention in participants, which could lead investors to misjudge the drug's commercial prospects.
- Commercial Viability Risks: The undisclosed safety risks raise serious questions about DCCR's commercial viability, potentially resulting in increased patient discontinuation rates, decreased prescriber willingness, and significant legal and reputational risks, thereby impacting the company's market performance.
- Investor Action Call: Affected investors are encouraged to apply to be lead plaintiffs by May 5, 2026, to share in any potential recovery from the lawsuit, underscoring the importance of legal avenues in protecting investor rights.
See More
Soleno Therapeutics Faces Securities Class Action Lawsuit
- Lawsuit Background: Hagens Berman reminds investors that Soleno Therapeutics (NASDAQ: SLNO) is facing a class action lawsuit for failing to disclose safety risks, urging investors to submit claims by May 5, 2026, for stock purchases made between March 26 and November 4, 2025.
- Safety Risk Allegations: The lawsuit alleges that Soleno concealed significant safety concerns regarding its flagship product VYKAT™ XR, including risks of fluid retention and heart failure in children, which could severely impact the company's reputation and future sales.
- Data Integrity Issues: Reports indicate that Soleno's Phase 3 clinical trials relied on a controversial physician whose data showed inconsistencies, potentially eroding investor trust in the company's data and affecting stock performance.
- Stock Price Volatility: On November 4, 2025, Soleno admitted to disruptions in the launch of DCCR, leading to a 27% drop in stock price in a single day, reflecting a severe lack of market confidence in the company's future prospects and potentially hindering future financing capabilities.
See More
